Determine the necessary mass, volume, or concentration for preparing a solution.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Moligand™, 10mM in DMSO Moligand™ for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 23 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Information
In vitro
Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase.
In vivo
Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A.
Cell Data
cell lines:
Concentrations:~32 nM
Incubation Time:72 hours
Powder Purity:≥99%
| ALogP | 3.6 |
|---|
| Isómeros SMILES | CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO |
|---|---|
| CAS alternativo | 302962-49-8,863127-77-9 |
| Número NSC | 732517 |
| Términos de entrada MeSH | (18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide;354825, BMS;BMS 354825;BMS-354825;BMS354825;dasatinib;N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methyl |
| Peso molecular | 488.01 |
| Reaxy-Rn | 9966762 |
| Reaxys-RN_link_address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=9966762&ln= |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Solubilidad | Solubility (25°C) In vitro DMSO: 46 mg/mL (196.35 mM); Ethanol: 13 mg/mL warmed with 50ºC Water: bath (55.49 mM); Water: Insoluble; |
|---|---|
| Punto de fusión (°C) | 280 °C |
| 1. Xiaofei Zhang, Mengyuan Lv, Yuyang Wang, Nan Zhang, Di Chen. (2025) Inner-wall biochar-coated pipette tip microextraction for rapid and sustainable determination of tyrosine kinase inhibitors in plasma. RSC Advances, 15 (40): (33536-33548). [PMID:40959299] [10.1039/D5RA05405B] |
| 2. Zhiming Wang, Jing Tan, Mengxuan Li, Can Gao, Wenwen Li, Jing Xu, Changchuan Guo, Zhenzhen Chen, Rong Cai. (2023) Clickable Photoreactive ATP-Affinity Probe for Global Profiling of ATP-Binding Proteins. ANALYTICAL CHEMISTRY, [PMID:37993803] [10.1021/acs.analchem.3c02694] |
| 3. Yao Liu, Zhichao He, Heng Liang, Minzhen Han, Jinxingyi Wang, Qian Liu, Yanping Guan. (2023) A high-throughput UHPLC-MS/MS method for the determination of eight anti-tumor drugs in plasma. ANALYTICAL BIOCHEMISTRY, [PMID:37429484] [10.1016/j.ab.2023.115230] |
| 4. Lu Yang, Jiaxi Xu, Zheng Xie, Faquan Song, Xin Wang, Rupei Tang. (2021) Carrier-free prodrug nanoparticles based on dasatinib and cisplatin for efficient antitumor in vivo. Asian Journal of Pharmaceutical Sciences, [PMID:35027952] [10.1016/j.ajps.2021.08.001] |
| 5. Zhao-Yang Wang, Hai-Long Wu, Yue-Yue Chang, Tong Wang, Wei Chen, Gao-Yan Tong, Ru-Qin Yu. (2021) Simultaneous determination of nine tyrosine kinase inhibitors in three complex biological matrices by using high-performance liquid chromatography–diode array detection combined with a second-order calibration method. JOURNAL OF SEPARATION SCIENCE, 44 (21): (3914-3923). [PMID:34463059] [10.1002/jssc.202100293] |
| 6. Deng-Pan Wu, Yan Zhou, Li-Xiang Hou, Xiao-Xiao Zhu, Wen Yi, Si-Man Yang, Tian-Yu Lin, Jin-Lan Huang, Bei Zhang, Xiao-Xing Yin. (2021) Cx43 deficiency confers EMT-mediated tamoxifen resistance to breast cancer via c-Src/PI3K/Akt pathway. International Journal of Biological Sciences, [PMID:34326682] [10.7150/ijbs.55453] |
| 7. Dawei Yang, Xiaoyu Tian, Yuchen Ye, Yin Liang, Jie Zhao, Tao Wu, Na Lu. (2021) Identification of GL-V9 as a novel senolytic agent against senescent breast cancer cells. LIFE SCIENCES, [PMID:33617857] [10.1016/j.lfs.2021.119196] |
| 8. Qingqing Li, Xianwei Yang, Peipei Zhang, Fei Mo, Peiru Si, Ximeng Kang, Menghan Wang, Jiye Zhang. (2021) Dasatinib loaded nanostructured lipid carriers for effective treatment of corneal neovascularization. Biomaterials Science, 9 (7): (2571-2583). [PMID:33589891] [10.1039/D0BM01599G] |
| 9. Yue-Yue Chang, Hai-Long Wu, Huan Fang, Tong Wang, Yang-Zi Ouyang, Xiao-Dong Sun, Gao-Yan Tong, Yu-Jie Ding, Ru-Qin Yu. (2020) Comparison of three chemometric methods for processing HPLC-DAD data with time shifts: Simultaneous determination of ten molecular targeted anti-tumor drugs in different biological samples. TALANTA, [PMID:33379025] [10.1016/j.talanta.2020.121798] |
| 10. Qianqian Wang, Yuanyuan Zheng, Bowen Deng, Di Chen, Liuqun Jia, Nian Shi. (2024) Automated kapok fiber-based pipette-tip solid-phase extraction coupled with liquid chromatography-tandem mass spectrometry for rapid and sensitive analysis of tyrosine kinase inhibitors in plasma. JOURNAL OF CHROMATOGRAPHY A, [PMID:39378625] [10.1016/j.chroma.2024.465420] |
| 11. Lisha Liu, Beiyuan Zhang, Xianggui Wu, Gang Cheng, Xiaopeng Han, Xiaofei Xin, Chao Qin, Lei Yang, Meirong Huo, Lifang Yin. (2024) Bioresponsive nanocomplex integrating cancer-associated fibroblast deactivation and immunogenic chemotherapy for rebuilding immune-excluded tumors. Nanomedicine-Nanotechnology Biology and Medicine, [PMID:38484918] [10.1016/j.nano.2024.102743] |
| 12. Xiaolan Zhou, Xiaofeng Zhu, Weixu Wang, Jing Wang, Haimei Wen, Yuqi Zhao, Jiayu Zhang, Qiushi Xu, Zhaozhao Zhao, Ting Ni. (2025) Comprehensive Cellular Senescence Evaluation to Aid Targeted Therapies. Research, [PMID:39822281] [10.34133/research.0576] |
| 13. Jiaxing Lei, Lei Wang, Chen Yang, Dongdong Li, Jiaxue Zhang, Jia Ma, Peipei Zhang, Qingqing Li, Jiye Zhang. (2024) Dasatinib and erianin co-loaded ion-responsive in-situ hydrogel for effective treatment of corneal neovascularization. JOURNAL OF CONTROLLED RELEASE, [PMID:39368709] [10.1016/j.jconrel.2024.10.001] |
| 14. Jing Ye, Yuanyuan Zheng, Xiangyu Li, Xingyi Jiang, Di Chen. (2024) Melt-blown polypropylene nonwoven as an efficient and eco-economic sorbent for pipette tip micro-solid phase extraction for the determination of tyrosine kinase inhibitors. ANALYTICA CHIMICA ACTA, [PMID:39396303] [10.1016/j.aca.2024.343240] |
| 15. Qianqian Wang, Yuwei Liu, Yuanyuan Zheng, Di Chen, Ya Xie, Nian Shi. (2024) MonoTip C18 pipette tip solid-phase extraction coupled with liquid chromatography-tandem mass spectrometry enables rapid and automated therapeutic drug monitoring of tyrosine kinase inhibitors. Arabian Journal of Chemistry, [PMID:] [10.1016/j.arabjc.2024.105976] |
| 16. Ninghong Li, Lu Liu, Dong Liu, Hengyi Yu, Guangjie Yang, Lihui Qiu, Yufei Chen, Dong Xiang, Xuepeng Gong. (2024) Simultaneous determination of three tyrosine kinase inhibitors and three triazoles in human plasma by LC-MS/MS: applications to therapeutic drug monitoring and drug-drug interaction studies. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, [PMID:39208604] [10.1016/j.jchromb.2024.124276] |
| 17. Haolin Song, Hongyi Chen, Qinjun Chen, Hongrui Fan, Chufeng Li, Yu Wang, Shilin Zhang, Xuwen Li, Boyu Su, Tao Sun, Chen Jiang. (2024) Size and Charge Dual-Switchable Nanoparticles for Achieving Chemosensitization and Immune Infiltration against Pancreatic Ductal Adenocarcinoma. ADVANCED FUNCTIONAL MATERIALS, [PMID:] [10.1002/adfm.202411643] |
| 18. Dong Wang, Mengrong Li, Tingting Dai, Xiangyu Zhang, Di Chen. (2025) Sensitive analysis of tyrosine kinase inhibitors in plasma using polypropylene fabric-solid phase extraction combined with liquid chromatography-tandem mass spectrometry. JOURNAL OF CHROMATOGRAPHY A, [PMID:40865307] [10.1016/j.chroma.2025.466315] |
| 19. Gankun Yuan, Ruyue Yang, Wenjing Wen, Zhaoyi Wei, Meiru Song, Lingyang Zhang, Kun Hou, Gaofeng Liang. (2025) Endoplasmic Reticulum-Targeted Photodynamic Therapy Combined with Autophagy Inhibition to Enhance Synergistic Immunotherapy for Triple-Negative Breast Cancer. CHEMISTRY-A EUROPEAN JOURNAL, [PMID:40350379] [10.1002/chem.202500146] |
| 20. Mengnan Yang, Yuqing Tong, Shaoping Yin, Hengchuan Zhang, Xiaowen Huang, Kai Yuan, Yanfei Hao, Jianping Zhou, Meirong Huo, Tingjie Yin. (2025) Microthrombi targeted nano-micelle synchronizing endothelial gap opening and matrix decompression for augmenting drug perfusion within pancreatic cancer. Acta Pharmaceutica Sinica B, [PMID:] [10.1016/j.apsb.2025.12.037] |
| 21. Wang Dong, Li Mengrong, Zhang Xiangyu, Chai Shiwei, Chen Di. (2026) Ultrasonic-assisted magnetic sorbent–wrapped stick dip extraction enables batch-scale and green LC-MS/MS analysis of tyrosine kinase inhibitors in plasma. ANALYTICAL AND BIOANALYTICAL CHEMISTRY, [PMID:41575510] [10.1007/s00216-026-06335-2] |
| 22. Gao Hengyuan, Lin Junqing, Chen Xiaobing, Su Yingshi, Huang Yibin, Zhang Yubo, Zhang Junchang, Xu Nan, Dai Xiaoyong. (2026) Microfluidic-based patient-derived organoids recapitulate thyroid cancer heterogeneity and reveal NF-κB-driven maturation for precision therapy. Journal of Translational Medicine, [PMID:41761289] [10.1186/s12967-026-07882-z] |
| 23. Jiansong Zhao, Tian Yin, Yaxin Deng, Hongbing Liu, Mingli Wei, Chenxiao Chu, Xinxin Liang, Xiaoshuang Bi, Haibing He, Jingxin Gou, Xing Tang, Yu Zhang. (2026) Harnessing semen-derived exosomes for noninvasive fundus drug delivery: A paradigm for exosome-based ocular fundus therapeutics. Science Advances, 12 (13): [PMID:] [10.1126/sciadv.adw7275] |
Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.
View Moligand™ grade guide →